Increased concentrations of bone sialoprotein in joint fluid after knee injury

L Stefan Lohmander, Tore Saxne, Dick Heinegård

Abstract
Objective—To detect evidence for localised changes in bone matrix metabolism after joint trauma and in post-traumatic osteoarthritis by quantification of bone sialoprotein in joint fluid and serum after knee injury in a cross sectional study.

Methods—Samples of knee joint fluid and serum were obtained from volunteers with normal knees (n = 19), patients with rupture of the anterior cruciate ligament isolated or combined with tear of a meniscus (n = 114), and patients with isolated meniscus lesions (n = 80). Concentrations of bone sialoprotein were determined by ELISA. Concentrations of other markers of joint tissue metabolism in these samples were determined in previous investigations.

Results—The median concentration of bone sialoprotein in joint fluid from healthy volunteers was 122 ng ml⁻¹ (range 41 to 183). Concentrations of bone sialoprotein were increased in both injury groups compared with the reference group (median for cruciate ligament injury 146 ng ml⁻¹, range 72 to 339; median for meniscal injury 166 ng ml⁻¹, range 75 to 376). After injury, bone sialoprotein increased quickly and remained increased for six months. Bone sialoprotein in joint fluid was increased only in samples from joints with normal or nearly normal (fibrillated) cartilage, and was within reference range in joints with radiographic signs of osteoarthritis. Bone sialoprotein concentrations in joints with cruciate ligament injury were positively correlated with levels of aggrecan and cartilage oligomeric matrix protein fragments, and with levels of stromelysin-1 and tissue inhibitor of metalloproteinase-1. The ratios between the concentrations of bone sialoprotein in joint fluid and serum were >1 in the majority of the cruciate ligament injury cases.

Conclusions—The release of significant amounts of bone sialoprotein into joint fluid in connection with acute joint trauma may be associated with injury to, and active remodelling of, the cartilage-bone interface and subchondral bone. The findings are consistent with dramatic shifts in cartilage, bone, and synovial metabolism following joint injury. Bone sialoprotein concentrations in synovial fluid may be a useful marker of subchondral injury and remodelling following joint injury.

Joint injury is associated with an increased rate of turnover of a number of macromolecules of articular cartilage and joint tissues. Thus the increased release into synovial fluid of fragments of matrix molecules, stromelysin (MMP-3), collagenase (MMP-1), and tissue inhibitor of metalloproteinases (TIMP-1) in both the acute and chronic phases after joint injury have been shown in cross sectional and longitudinal investigations. These changes in cartilage matrix metabolism after injury may be relevant to the increased risk for development of osteoarthritis in these patients.

Assays of fragments of bone matrix molecules in joint fluid, serum, and urine suggest that changes occur also in bone matrix metabolism in osteoarthritis and rheumatoid arthritis. These findings are consistent with the suggestions that changes in metabolism, structure, and function of both bone and cartilage are cardinal features in the pathology of osteoarthritis and rheumatoid arthritis.

Magnetic resonance imaging of the acutely injured knee often reveals subchondral bone lesions in the presence of normal plain radiographs and normal arthroscopic findings. These previously unrecognised lesions may induce long term changes in the structure and biomechanical properties of the joint and could be important for the future development of post-traumatic osteoarthritis.

Bone sialoprotein is a bone specific molecule produced by osteoblasts with an Mr of 57 kDa, which constitutes 12% of the non-collagenous proteins of bone matrix. The function of bone sialoprotein is unknown, but it binds tightly to hydroxyapatite and to cells. The protein backbone of 33.6 kDa contains an RGD sequence, which can mediate binding to an integrin, the α,β₃ receptor. The protein shows the highest level of synthesis at the cartilage-bone interface in the growth cartilage and is markedly enriched in the interface between articular cartilage and bone, the tidemark, and in the cement lines and mineralising osteoid. The primary cell expressing bone sialoprotein is an osteoblast, but it is also expressed by hypertrophic chondrocytes in the growth plate.

Lund University Hospital, Lund, Sweden: Department of Orthopaedics, L S Lohmander

Department of Rheumatology
T Saxne

Department of Cell and Molecular Biology, Lund University, Lund, Sweden D Heinegård

Correspondence to: Stefan Lohmander, Department of Orthopaedics, University Hospital, S-22185 Lund, Sweden.

Accepted for publication 25 April 1996

Bone sialoprotein in joint fluid after knee injury

Patient characteristics. Median (range) are given for age (ears), time (weeks after injury), volume (ml).

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Males</th>
<th>Age</th>
<th>Time</th>
<th>Vol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>19</td>
<td>14</td>
<td>29 (17-43)</td>
<td>–</td>
<td>2 (1-5)</td>
</tr>
<tr>
<td>ACL</td>
<td>114</td>
<td>80</td>
<td>32 (14-67)</td>
<td>105</td>
<td>6 (1-70)</td>
</tr>
<tr>
<td>Meniscus</td>
<td>80</td>
<td>70</td>
<td>45 (16-70)</td>
<td>44</td>
<td>5 (1-90)</td>
</tr>
</tbody>
</table>

ACL, anterior cruciate ligament injury group; Meniscus, meniscus injury group.

To identify alterations particularly at the bone-cartilage interface, we have assayed bone sialoprotein concentrations in joint fluid and serum after knee injury in a cross sectional study to detect evidence for localised changes in bone matrix metabolism after joint trauma and in post-traumatic osteoarthritis.

Methods

Samples of knee joint fluid and serum were obtained from 194 patients and 19 volunteers with healthy knees (control group). In this cross sectional study, each volunteer and patient supplied a sample at one time point only. For patients, sampling took place at varying times after knee injury or the beginning of symptoms. The control group has been described in more detail previously.26 The study groups were: anterior cruciate ligament rupture isolated or combined with a tear of meniscus or collateral ligament (ACL group), and isolated meniscus lesion (meniscus group) (table). Diagnosis was made by arthroscopy, radiography, and clinical examination. No patient was treated by surgery before serum or joint fluid sampling. Pharmacological treatment was limited to the occasional analgesic or non-steroidal anti-inflammatory drug. The degree of joint changes was assessed by arthroscopy and standing radiographs and scored on a scale of 1 to 10, where 1 represents a normal joint by arthroscopy and radiography, 2-5 represents increasing degrees of joint cartilage changes by arthroscopy in a joint with a normal radiograph, and 6-10 increasing degrees of radiographic joint space loss on standing radiographs consistent with osteoarthritis.27 All procedures were approved by the ethics review board of the University.

Bone sialoprotein in joint fluid and serum was quantified by immunoassay, using a rabbit anti-human-bone sialoprotein antibody and human bone sialoprotein as standard.12 Intra-assay variation for both synovial fluid and serum was < 6 %, and interassay variation <10%. Bone sialoprotein reactivity in this immunoassay is not changed by repeated freeze-thawing of joint fluid or serum. Aggreccan fragments (AGN), cartilage oligomeric matrix protein (COMP), C-propeptide of collagen type II (PC2C), MMP-1, MMP-3, and TIMP-1 were previously assayed in these samples by dye precipitation or immunoassays, respectively.5-3 Significance of differences between groups were determined by Mann-Whitney test or Kruskal-Wallis one way analysis of variance on ranks where appropriate, with comparison of subgroups v the control group by Dunn’s method. Correlations were estimated by Spearman rank correlation test. A P value < 0.05 was considered significant for differences and correlations, and all differences and correlations discussed as such are significant at this level or better.

Results

JOINT FLUID

Concentrations of bone sialoprotein were increased in both injury groups compared with control (fig 1). The median concentration of bone sialoprotein in joint fluid from the control group was 121.6 ng ml\(^{-1}\) (range 40.8 to 183.3). Reference values for bone sialoprotein in joint fluid have not previously been published.

After knee injury, bone sialoprotein concentrations quickly increased and were raised for up to two years after injury (fig 2). At later times, concentrations were not different from those in the control group. Concentrations did not differ between ACL and meniscus injuries in the various subgroups, and the temporal concentration patterns were similar in these two different types of joint injury.

When bone sialoprotein concentrations in samples obtained later than 26 weeks after injury (fig 2) were related to osteoarthritis stage, only those samples obtained from normal or nearly normal (fibrillated cartilage) joints (with regard to arthroscopy and radiography findings) had increased median concentrations (fig 3). At more advanced stages of cartilage changes, including those joints with radiographic signs of osteoarthritis, median concentrations of bone sialoprotein did not differ from the REF group.

Bone sialoprotein concentrations in joint fluid samples from patients with anterior cruciate ligament injury (ACL group) were positively correlated with AGN, COMP, MMP-3, and TIMP-1 (but not MMP-1 or PC2C) levels, with \( r \) values of 0.60, 0.58, 0.50, and 0.54, respectively, and with \( P \) values < 0.001 (fig 4, data shown only for COMP).

![Figure 1](http://ard.bmj.com/)

**Figure 1** Bone sialoprotein (BSP) in joint fluid in the different study groups. Box represents 25th-75th centiles, line median, whiskers 10th and 90th centiles, symbols represent individual values outside those range. Bone sialoprotein groups differed from the control group (\( P < 0.001 \)); the meniscus injury group differed from the cruciate ligament injury group (\( P = 0.027 \)).
contrast, bone sialoprotein concentrations in joint fluids from patients with meniscus tears did not correlate well enough with any of these markers to give $r_s$ values greater than 0.5 ($r_s$ values between 0.25 and 0.08, with $P$ values between 0.03 and 0.5). However, correlations between AGN and COMP or between MMP-3 and MMP-1 concentrations, were similarly good in these two diagnostic groups with $r_s$ values of 0.7 and 0.8, respectively, and $P$ values < 0.001.

**SERUM**

The median serum concentration of bone sialoprotein in the ACL group (age range 14 to 67 years) was 114 ng ml$^{-1}$ (range 70-220 ng ml$^{-1}$), compared with a median concentration of 75 ng ml$^{-1}$ for a previously published healthy control group aged 21-70 years. Concentrations of bone sialoprotein in serum did not change in relation to the time after injury or stage of osteoarthritis and did not correlate with serum concentrations of keratan sulphate or stromelysin-1 (data not shown).

The ratios between the concentrations of bone sialoprotein in joint fluid and serum were >1 in 45 out of the 53 cases (median ratio 1.3 for this group, 1.0 for the remaining eight patients) where joint fluid and serum from the same patient were assayed. The ratios between synovial fluid and serum concentrations of bone sialoprotein did not change in relation to time after injury (Fig 5) or in relation to OA stage (data not shown). Interestingly, the range of ratios of bone sialoprotein in synovial fluid to bone sialoprotein in serum increased markedly with time after injury (Fig 5).

**Discussion**

Changes in metabolism, structure, and function of bone and cartilage are prominent features in the pathology of both osteoarthritis and rheumatoid arthritis. In primary osteoarthritis as well as in post-traumatic osteoarthritis, elevated bone sialoprotein concentrations were found in joint fluid, serum, and synovial fluid.

![Figure 2](image1.png)

Figure 2. Bone sialoprotein (BSP) in joint fluid after cruciate ligament and/or meniscus lesion. Patients ordered by time after injury and divided into time windows indicated on horizontal axis. The number of patients in the subgroups were 23, 19, 20, 25, 29, 22, 22, and 34, respectively. The BSP concentrations in first five subgroups (up to 104 weeks after injury) were increased as compared to the control group ($P < 0.001$). Shaded zone indicates 25th-75th centiles for control group. See fig 1 for legend.

![Figure 3](image2.png)

Figure 3. Bone sialoprotein (BSP) in joint fluid after cruciate ligament and/or meniscus lesion in relation to osteoarthritis (OA) stage by arthroscopy and radiography. Samples collected within 26 weeks of knee injury were excluded. The number of patients in the subgroups were 48, 18, 12, 13, 13, and 29, respectively. The BSP concentrations in the first two subgroups (OA scores 1 and 2) were increased as compared to the control group ($P < 0.001$). Shaded zone indicates 25th-75th centiles for reference group. See fig 1 for legend.

![Figure 4](image3.png)

Figure 4. Correlation between concentrations of bone sialoprotein (BSP) and COMP in joint fluid samples from patients with anterior cruciate ligament (ACL) injury ($r_s = 0.58, P < 0.001, n = 108$).

![Figure 5](image4.png)

Figure 5. Ratios of concentrations of bone sialoprotein (BSP) in joint fluid and serum in relation to time after injury for patients with anterior cruciate ligament (ACL) injury. See fig 1 for legend. The numbers of patients in the subgroups were 10, 11, 10, 11, and 11, respectively.
Bone sialoprotein in joint fluid after knee injury

Bone sialoprotein in joint fluid after knee injury

Bone sialoprotein concentrations in joint fluid following injury and during development of post-traumatic osteoarthritis were raised only in the normal or near normal joint (with regard to arthroscopy and plain radiography findings). This is in agreement with the finding that median bone sialoprotein concentrations were increased only up to about two years after injury. Perhaps this corresponds to the period of most active remodelling of joint bone and tidemark after injury. The fact that the concentrations in joint fluid of fragments of cartilage matrix molecules such as AGN and COMP remain increased for much longer periods after injury is consistent with a more extensive metabolic perturbation of cartilage metabolism and its ultimate destruction in osteoarthritis.

In contrast to rheumatoid arthritis, bone sialoprotein concentrations did not increase with increasing joint destruction during developing post-injury osteoarthritis. This difference may be due to the differences in juxta-articular bone remodelling and destruction in these two conditions. It is possible that major alterations at the cartilage-bone interface occur early in those injuries which lead to progressive osteoarthritis. Notably, the levels of joint fluid bone sialoprotein showed a wide distribution early after injury. It may be that the cases with high bone sialoprotein levels will show a high future incidence of osteoarthritis.

We conclude that bone sialoprotein concentrations are a marker of the extent of turnover rate of bone sialoprotein, which may in turn reflect the degree of disease involvement of a bone matrix compartment rich in bone sialoprotein.

In the present study, we detected significant increases in joint fluid concentrations of fragments of this bone specific protein in connection with knee injury. The release of significant amounts of this protein to joint fluid in connection with acute joint trauma and in the months following may be associated with injury to, and active remodelling of, the cartilage-bone interface and the subchondral bone in the period following the trauma. Joint fluid bone sialoprotein concentrations in patients with cruciate ligament injury correlated well with concentrations of aggrecan and COMP fragments, and with MMP-3 and TIMP-1 concentrations. This is consistent with the notion that dramatic shifts in both cartilage, bone, and synovial metabolism occur following this injury, and that these changes may be causally related. Since the ratio of bone sialoprotein in synovial fluid to that in serum was greater than 1, it is reasonable to conclude that a significant proportion of the bone sialoprotein in joint fluid is locally derived. There was a lesser degree of correlation between joint fluid concentrations of bone sialoprotein on the one hand, and aggrecan, COMP, MMP-3, and TIMP-1 concentrations on the other in samples from patients with meniscus injury. This is consistent with the different injury mechanisms in anterior cruciate ligament and meniscus injuries, and with previously shown differences in marker release for these two patient groups.

Bone sialoprotein concentrations in joint fluid following injury and during development of post-traumatic osteoarthritis were raised only in the normal or near normal joint (with regard to arthroscopy and plain radiography findings). This is in agreement with the finding that median bone sialoprotein concentrations were increased only up to about two years after injury. Perhaps this corresponds to the period of most active remodelling of joint bone and tidemark after injury. The fact that the concentrations in joint fluid of fragments of cartilage matrix molecules such as AGN and COMP remain increased for much longer periods after injury is consistent with a more extensive metabolic perturbation of cartilage metabolism and its ultimate destruction in osteoarthritis.

In contrast to rheumatoid arthritis, bone sialoprotein concentrations did not increase with increasing joint destruction during developing post-injury osteoarthritis. This difference may be due to the differences in juxta-articular bone remodelling and destruction in these two conditions. It is possible that major alterations at the cartilage-bone interface occur early in those injuries which lead to progressive osteoarthritis. Notably, the levels of joint fluid bone sialoprotein showed a wide distribution early after injury. It may be that the cases with high bone sialoprotein levels will show a high future incidence of osteoarthritis.

We conclude that bone sialoprotein concentrations are a marker of the extent of turnover rate of bone sialoprotein, which may in turn reflect the degree of disease involvement of a bone matrix compartment rich in bone sialoprotein.

In the present study, we detected significant increases in joint fluid concentrations of fragments of this bone specific protein in connection with knee injury. The release of significant amounts of this protein to joint fluid in connection with acute joint trauma and in the months following may be associated with injury to, and active remodelling of, the cartilage-bone interface and the subchondral bone in the period following the trauma. Joint fluid bone sialoprotein concentrations in patients with cruciate ligament injury correlated well with concentrations of aggrecan and COMP fragments, and with MMP-3 and TIMP-1 concentrations. This is consistent with the notion that dramatic shifts in both cartilage, bone, and synovial metabolism occur following this injury, and that these changes may be causally related. Since the ratio of bone sialoprotein in synovial fluid to that in serum was greater than 1, it is reasonable to conclude that a significant proportion of the bone sialoprotein in joint fluid is locally derived. There was a lesser degree of correlation between joint fluid concentrations of bone sialoprotein on the one hand, and aggrecan, COMP, MMP-3, and TIMP-1 concentrations on the other in samples from patients with meniscus injury. This is consistent with the different injury mechanisms in anterior cruciate ligament and meniscus injuries, and with previously shown differences in marker release for these two patient groups.

Bone sialoprotein concentrations in joint fluid following injury and during development of post-traumatic osteoarthritis were raised only in the normal or near normal joint (with regard to arthroscopy and plain radiography findings). This is in agreement with the finding that median bone sialoprotein concentrations were increased only up to about two years after injury. Perhaps this corresponds to the period of most active remodelling of joint bone and tidemark after injury. The fact that the concentrations in joint fluid of fragments of cartilage matrix molecules such as AGN and COMP remain increased for much longer periods after injury is consistent with a more extensive metabolic perturbation of cartilage metabolism and its ultimate destruction in osteoarthritis.

In contrast to rheumatoid arthritis, bone sialoprotein concentrations did not increase with increasing joint destruction during developing post-injury osteoarthritis. This difference may be due to the differences in juxta-articular bone remodelling and destruction in these two conditions. It is possible that major alterations at the cartilage-bone interface occur early in those injuries which lead to progressive osteoarthritis. Notably, the levels of joint fluid bone sialoprotein showed a wide distribution early after injury. It may be that the cases with high bone sialoprotein levels will show a high future incidence of osteoarthritis.

We conclude that bone sialoprotein concentrations are a marker of the extent of turnover rate of bone sialoprotein, which may in turn reflect the degree of disease involvement of a bone matrix compartment rich in bone sialoprotein.


Increased concentrations of bone sialoprotein in joint fluid after knee injury.

L S Lohmander, T Saxne and D Heinegård

doi: 10.1136/ard.55.9.622

Updated information and services can be found at:
http://ard.bmj.com/content/55/9/622

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/